Anti-Cancer Agents and Biological Therapy
Clinical Pharmacology of Anti-Cancer Agents
Oncological Emergencies
Latest ESMO videos
Featured medwireNews
Abemaciclib Improves Invasive DFS For Select High-Risk Early Breast Cancer Patients
AURA3 Fails To Demonstrate OS Benefit For Osimertinib
Veliparib–Chemotherapy ‘A Compelling Option’ For BRCA-Mutated Breast Cancer
BRAF-Mutated Biliary Tract Cancer Patients May Benefit From Dabrafenib Plus Trametinib
TRITON2 Supports Rucaparib For BRCA1/2-Mutated Metastatic CRPC
E-Learning
ESMO V-Learning: BRCA Across Tumour Types
ESMO E-Learning: Next Generation Drugs in Kidney Cancer
ESMO E-Learning: Management of Cancer Associated Thrombosis
ESMO E-Learning: Treatment of Locally Advanced NSCLC with Chemo-radiotherapy
ESMO E-Learning: Testicular Cancer: Treatment Strategies and Fertility Preservation
Meeting resources
Participants Clinical Case Discussion: Treatment of Metastatic RCC Patient with Hepatotoxicity
Presenter: B. Oztosun, TR
Session: SESSION 6 - Side Effects
Resources:
Presentation
Webcast
Participants Clinical Case Discussion: 4 Years Survival of mRCC Without Immunotherapy
Presenter: V. Talreja, IN
Session: SESSION 6 - Side Effects
Resources:
Presentation
Webcast
Immunotherapy
Presenter: L. Albiges, FR
Session: SESSION 6 - Side Effects
Resources:
Presentation
Webcast
Tyrosine Kinase Inhibitors and mTOR Inhibitors in RCC
Presenter: T. Rajasekaran, SG
Session: SESSION 6 - Side Effects
Resources:
Presentation
Webcast
Chemotherapy
Presenter: R. Kanesvaran, SG
Session: SESSION 6 - Side Effects
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.